CAR-T细胞在血液恶性肿瘤治疗中的细胞动力学特征和研究进展  

Cellular dynamics and research progress of CAR-T cells in treating hematological malignancies

作　　者：张凯杰 边诣聪[1,3] 王燕 缪丽燕[1,2,3,4] ZHANG Kaijie;BIAN Yicong;WANG Yan;MIAO Liyan(Department of Clinical Pharma-cology Research Lab,the First Affiliated Hospital of Soochow University,Jiangsu Suzhou 215006,China;National Clinical Research Center for Hematologic Diseases,the First Affiliated Hospital of Soochow University,Jiangsu Suzhou 215006,China;Institute for Interdisciplinary Drug Research and Translational Sci-ences,Soochow University,Jiangsu Suzhou 215100,China;College of Pharmaceutical Sciences,Soochow University,Jiangsu Suzhou 215100,China)

机构地区：[1]苏州大学附属第一医院临床药理研究室,江苏苏州215006 [2]苏州大学附属第一医院国家血液研究中心,江苏苏州215006 [3]苏州大学药物研究和转化交叉研究所,江苏苏州215100 [4]苏州大学药学院,江苏苏州215100

出　　处：《中国医院药学杂志》2025年第3期337-342,共6页Chinese Journal of Hospital Pharmacy

基　　金：国家血液系统疾病临床医学研究中心转化研究开放课题(编号:2020WSC07);中国药学会医院药学科研专项资助项目(编号:CPA-Z05-ZC-2021-002);苏州市科技发展计划项目(编号:SKJYD2021159)。

摘　　要：嵌合抗原受体T(chimeric antigen receptor T,CAR-T)细胞疗法作为新型的细胞免疫治疗手段,在血液恶性肿瘤治疗中有着良好的应用前景。CAR-T细胞作为一种“活”药物,具有体内增殖分化特性,并在体内呈现特殊的细胞药动学(pharmacokinetics,PK)行为。既往研究表明,CAR-T细胞体内动力学特征可能与CAR-T细胞治疗的临床疗效和安全性有关。CAR-T细胞体内动力学行为对于明确CAR-T细胞体内作用机制,进一步指导CAR-T细胞临床精准治疗具有重要意义。为此,该文对血液恶性肿瘤治疗中的CAR-T细胞药动学及其影响因素的研究进展进行综述,以期为临床CAR-T细胞安全有效治疗提供参考。Chimeric antigen receptor T(CAR-T)cell therapy is a novel cellular immunotherapeutic means that holds great promise in the treatment of hematological malignancies.CAR-T cells,as a kind of“living”drug,have the property of in vivo proliferation and differentiation,as well as special cellular pharmacokinetic(PK)behavior.Previous studies have shown that the in vivo kinetic characteristics of CAR-T cells may be associated with the clinical efficacy and safety of CAR-T therapy.It is important to clarify the kinetic behavior of CAR-T cells to grasp the mechanism of CAR-T cells,thus further guiding the precision therapy of CAR-T.Therefore,this article reviewed the research progress on CAR-T cell pharmacokinetics and its influencing factors in the treatment of hematological malignancies,in order to provide references for the safe and effective treatment of CAR-T cells in clinical practice.

关 键 词：CAR-T 血液恶性肿瘤 细胞动力学 影响因素 

分 类 号：R969.1[医药卫生—药理学]